What are the long‑term risks of disease‑modifying anti‑rheumatic drugs (DMARDs) in adults with rheumatoid arthritis or similar inflammatory conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Long-Term Risks of DMARDs in Rheumatoid Arthritis

The long-term risks of DMARDs vary significantly by drug class, with infections being the most common concern across all agents, while JAK inhibitors carry specific elevated risks for herpes zoster and venous thromboembolism that require heightened vigilance. 1

Infection Risks

Serious infections are more common with biological DMARDs than conventional synthetic DMARDs. 1 The infection risk hierarchy is critical for clinical decision-making:

  • Herpes zoster: JAK inhibitors demonstrate substantially higher risk compared to biological DMARDs (HR 2.61-2.90) 2
  • Tuberculosis: Infliximab and adalimumab carry higher TB risk than etanercept, but JAK inhibitors show no increased TB risk compared to biological DMARDs 1
  • Pneumocystis pneumonia: No clear difference between JAK inhibitors and biological DMARDs 2
  • Non-TNF biologics (abatacept, rituximab, tocilizumab) are consistently linked to increased pneumonia-related hospitalizations and recurrence 3

Malignancy Risks

The malignancy data provides reassurance for most agents:

  • Non-melanoma skin cancer is increased in RA patients using DMARDs compared to the general population, but no specific DMARD is implicated 1
  • JAK inhibitors show no increased malignancy risk compared to biological DMARDs at 2nd and 3rd lines of therapy 2
  • IL-6 inhibitors demonstrate a lower malignancy risk (HR 0.73) compared to abatacept 4
  • Rituximab shows increased malignancy risk (HR 1.30) compared to abatacept 4

Cardiovascular and Thromboembolic Events

This represents the most nuanced risk category requiring careful patient selection:

Venous thromboembolism risk is elevated with JAK inhibitors compared to biological DMARDs, driven primarily by pulmonary embolism. 1 However, the cardiovascular picture is more complex:

  • No consistent evidence of increased major adverse cardiovascular events (MACE) with JAK inhibitors versus biological DMARDs 1
  • Multiple large observational studies show conflicting results, with some showing increased CV risk with JAKi and others showing no difference 1
  • TNF inhibitors show increased heart failure risk (HR 1.54) compared to abatacept 4
  • Rituximab demonstrates elevated heart failure risk (HR 1.52) and VTE risk (HR 1.43) compared to abatacept 4

Other Significant Risks

  • Gastrointestinal perforation: Reported across multiple studies, particularly with IL-6 inhibitors 1
  • Demyelinating disease: Documented risk requiring neurological monitoring 1
  • Tocilizumab: Associated with higher hospitalization risk (RD 0.205) compared to etanercept 5
  • Tofacitinib: Linked to higher gastritis risk (RD 0.055) compared to etanercept 5

Critical Clinical Pitfalls

The most important caveat is that a substantial proportion of recent safety data relies on claims databases, which carry significant methodological limitations for safety research. 1 This means:

  • Real-world risks may differ from reported estimates
  • Residual confounding cannot be excluded despite sophisticated statistical adjustments
  • Selection bias affects observational comparisons

Surprisingly, recent literature shows minimal focus on glucocorticoid safety outcomes despite their widespread use. 1

Risk-Stratified Approach

For patients with:

  • High cardiovascular risk or history of VTE: Avoid JAK inhibitors; prefer TNF inhibitors (particularly etanercept over infliximab/adalimumab)
  • High infection risk or immunosuppression: Avoid non-TNF biologics (rituximab, tocilizumab, abatacept); consider TNF inhibitors
  • History of malignancy: Avoid rituximab; IL-6 inhibitors may offer protective benefit
  • TB risk or endemic TB exposure: Prefer etanercept or JAK inhibitors over infliximab/adalimumab
  • Herpes zoster history: Avoid JAK inhibitors; ensure vaccination before initiating therapy

The evidence base has expanded substantially in 2023-2025, with most new data focusing on JAK inhibitor safety, reflecting regulatory concerns from the EMA regarding cardiovascular and thromboembolic events. 1 This recent focus provides the most robust comparative safety data for this drug class.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.